Savara Inc. (NASDAQ:SVRA) Q4 2019 Earnings Conference Call - Final Transcript
Mar 12, 2020 • 04:30 pm ET
aPAP. And I would like to thank all the patients and their families, and the investigators who participated in the study. We're grateful for your commitments in helping us to advance research in this debilitating disease.
With regard to Molgradex and aPAP, we move into 2020 with renewed clarity and how to execute on our priorities, focusing our attention on IMPALA 2. We look forward to keeping you updated as we make progress on this front. As for NTM, we will continue to assess the outcomes of OPTIMA in combination with the results from ENCORE once they're available so we can make a more informed decision about the future of this development program.
As always, we appreciate your continued support and thank you everybody for dialing in. And let me hand the call back to Alison for analyst questions.